190 related articles for article (PubMed ID: 18045968)
1. Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature.
Ding BS; Hong N; Murciano JC; Ganguly K; Gottstein C; Christofidou-Solomidou M; Albelda SM; Fisher AB; Cines DB; Muzykantov VR
Blood; 2008 Feb; 111(4):1999-2006. PubMed ID: 18045968
[TBL] [Abstract][Full Text] [Related]
2. Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature.
Ding BS; Gottstein C; Grunow A; Kuo A; Ganguly K; Albelda SM; Cines DB; Muzykantov VR
Blood; 2005 Dec; 106(13):4191-8. PubMed ID: 16144802
[TBL] [Abstract][Full Text] [Related]
3. Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema.
Danielyan K; Ding BS; Gottstein C; Cines DB; Muzykantov VR
J Pharmacol Exp Ther; 2007 Jun; 321(3):947-52. PubMed ID: 17389242
[TBL] [Abstract][Full Text] [Related]
4. Towards effective and safe thrombolysis and thromboprophylaxis: preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets.
Wang X; Palasubramaniam J; Gkanatsas Y; Hohmann JD; Westein E; Kanojia R; Alt K; Huang D; Jia F; Ahrens I; Medcalf RL; Peter K; Hagemeyer CE
Circ Res; 2014 Mar; 114(7):1083-93. PubMed ID: 24508759
[TBL] [Abstract][Full Text] [Related]
5. Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.
Zaitsev S; Spitzer D; Murciano JC; Ding BS; Tliba S; Kowalska MA; Marcos-Contreras OA; Kuo A; Stepanova V; Atkinson JP; Poncz M; Cines DB; Muzykantov VR
Blood; 2010 Jun; 115(25):5241-8. PubMed ID: 20410503
[TBL] [Abstract][Full Text] [Related]
6. Urokinase mediates fibrinolysis in the pulmonary microvasculature.
Bdeir K; Murciano JC; Tomaszewski J; Koniaris L; Martinez J; Cines DB; Muzykantov VR; Higazi AA
Blood; 2000 Sep; 96(5):1820-6. PubMed ID: 10961882
[TBL] [Abstract][Full Text] [Related]
7. Design and evaluation of a thrombin-activable plasminogen activator.
Yang WP; Goldstein J; Procyk R; Matsueda GR; Shaw SY
Biochemistry; 1994 Mar; 33(8):p606-12. PubMed ID: 8117652
[TBL] [Abstract][Full Text] [Related]
8. PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress.
Christofidou-Solomidou M; Scherpereel A; Wiewrodt R; Ng K; Sweitzer T; Arguiri E; Shuvaev V; Solomides CC; Albelda SM; Muzykantov VR
Am J Physiol Lung Cell Mol Physiol; 2003 Aug; 285(2):L283-92. PubMed ID: 12851209
[TBL] [Abstract][Full Text] [Related]
9. A recombinant antibody-targeted plasminogen activator with high affinity for activated platelets increases thrombolytic potency in vitro and in vivo.
Wan H; Liu Z; Xia X; Gu J; Wang B; Liu X; Zhu M; Li P; Ruan C
Thromb Res; 2000 Feb; 97(3):133-41. PubMed ID: 10680644
[TBL] [Abstract][Full Text] [Related]
10. Platelet endothelial cell adhesion molecule targeted oxidant-resistant mutant thrombomodulin fusion protein with enhanced potency in vitro and in vivo.
Carnemolla R; Greineder CF; Chacko AM; Patel KR; Ding BS; Zaitsev S; Esmon CT; Muzykantov VR
J Pharmacol Exp Ther; 2013 Nov; 347(2):339-45. PubMed ID: 23965383
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of recombinant human single-chain urokinase-type plasminogen activator variants resistant to plasmin and thrombin.
Miyake T; Hibino Y; Kobayashi Y; Yokoyama M; Watabe K; Ohmori M
J Biochem; 1988 Oct; 104(4):643-7. PubMed ID: 2977134
[TBL] [Abstract][Full Text] [Related]
12. A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
Schneider J; Hauser R; Hennies HH; Korioth J; Steffens G; Wnendt S
Thromb Haemost; 1997 Mar; 77(3):535-9. PubMed ID: 9066007
[TBL] [Abstract][Full Text] [Related]
13. Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation.
Ding BS; Hong N; Christofidou-Solomidou M; Gottstein C; Albelda SM; Cines DB; Fisher AB; Muzykantov VR
Am J Respir Crit Care Med; 2009 Aug; 180(3):247-56. PubMed ID: 19342415
[TBL] [Abstract][Full Text] [Related]
14. Thrombin stimulation of platelets induces plasminogen activation mediated by endogenous urokinase-type plasminogen activator.
Lenich C; Liu JN; Gurewich V
Blood; 1997 Nov; 90(9):3579-86. PubMed ID: 9345041
[TBL] [Abstract][Full Text] [Related]
15. Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential.
Lijnen HR; Wnendt S; Schneider J; Janocha E; Van Hoef B; Collen D; Steffens GJ
Eur J Biochem; 1995 Nov; 234(1):350-7. PubMed ID: 8529664
[TBL] [Abstract][Full Text] [Related]
16. Interaction of single-chain urokinase with its receptor induces the appearance and disappearance of binding epitopes within the resultant complex for other cell surface proteins.
Higazi AA; Upson RH; Cohen RL; Manuppello J; Bognacki J; Henkin J; McCrae KR; Kounnas MZ; Strickland DK; Preissner KT; Lawler J; Cines DB
Blood; 1996 Jul; 88(2):542-51. PubMed ID: 8695802
[TBL] [Abstract][Full Text] [Related]
17. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
Holvoet P; Laroche Y; Lijnen HR; Van Hoef B; Brouwers E; De Cock F; Lauwereys M; Gansemans Y; Collen D
Eur J Biochem; 1992 Dec; 210(3):945-52. PubMed ID: 1483477
[TBL] [Abstract][Full Text] [Related]
18. Platelet-endothelial cell adhesion molecule-1-directed immunotargeting to cardiopulmonary vasculature.
Scherpereel A; Rome JJ; Wiewrodt R; Watkins SC; Harshaw DW; Alder S; Christofidou-Solomidou M; Haut E; Murciano JC; Nakada M; Albelda SM; Muzykantov VR
J Pharmacol Exp Ther; 2002 Mar; 300(3):777-86. PubMed ID: 11861781
[TBL] [Abstract][Full Text] [Related]
19. Vascular immunotargeting to endothelial determinant ICAM-1 enables optimal partnering of recombinant scFv-thrombomodulin fusion with endogenous cofactor.
Greineder CF; Chacko AM; Zaytsev S; Zern BJ; Carnemolla R; Hood ED; Han J; Ding BS; Esmon CT; Muzykantov VR
PLoS One; 2013; 8(11):e80110. PubMed ID: 24244621
[TBL] [Abstract][Full Text] [Related]
20. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
Nagashima M; Werner M; Wang M; Zhao L; Light DR; Pagila R; Morser J; Verhallen P
Thromb Res; 2000 May; 98(4):333-42. PubMed ID: 10822080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
